Almirall S.A. Total Assets
Almirall S.A. total assets. Based on the latest financial reports, Almirall S.A. (ALM) holds total assets worth €2.36 Billion EUR (≈ $2.76 Billion USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see ALM cash generation efficiency for how efficiently the company converts equity into cash flow.
Total Assets of Almirall S.A. (2003–2024)
Total assets of Almirall S.A. from 2003 to 2024. This chart illustrates how Almirall S.A.'s total assets have evolved over time, based on quarterly financial data. See ALM share price today for real-time trading data and today's change.
Almirall S.A. - Asset Composition Analysis
Almirall S.A. Total Assets Breakdown (December 2024)
Almirall S.A. total assets breakdown as of December 2024. Almirall S.A.'s total assets of €2.36 Billion consist of 30.9% current assets and 69.1% non-current assets. Explore Almirall S.A. current assets vs equity to assess how much short-term liquidity the company maintains relative to its equity base.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 15.7% |
| Accounts Receivable | €151.44 Million | 6.3% |
| Inventory | €171.69 Million | 7.2% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €936.97 Million | 39.1% |
| Goodwill | €315.97 Million | 13.2% |
Asset Composition Trend (2003–2024)
This chart illustrates how Almirall S.A.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Almirall S.A.'s current assets represent 30.9% of total assets in 2024, an increase from 0.0% in 2003.
- Cash Position: Cash and equivalents constituted 15.7% of total assets in 2024, up from 4.5% in 2003.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 52.0% of total assets, an increase from 24.0% in 2003.
- Asset Diversification: The largest asset category is intangible assets at 39.1% of total assets.
Almirall S.A. Competitors by Total Assets
Key competitors of Almirall S.A. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
GALDERMA GROUP AG
NYSE:GALDY
|
USA | $13.39 Billion |
|
Takeda Pharmaceutical Company Limited
F:TKDA
|
Germany | €15.41 Trillion |
|
Galderma Group N
SW:GALD
|
Switzerland | CHF12.88 Billion |
|
Enzymatica publ AB
ST:ENZY
|
Sweden | Skr149.24 Million |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603
|
China | CN¥13.98 Billion |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566
|
China | CN¥17.01 Billion |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518
|
China | CN¥13.68 Billion |
|
Walvax BioTech
SHE:300142
|
China | CN¥10.50 Billion |
Almirall S.A. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.55 | 2.61 | 1.03 |
| Quick Ratio | 1.93 | 1.99 | 0.76 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €472.00 Million | €434.10 Million | €15.19 Million |
Almirall S.A. - Advanced Valuation Insights
This section examines the relationship between Almirall S.A.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.97 |
| Latest Market Cap to Assets Ratio | 1.10 |
| Asset Growth Rate (YoY) | 0.9% |
| Total Assets | €2.40 Billion |
| Market Capitalization | $2.63 Billion USD |
Valuation Analysis
Above Book Valuation: The market values Almirall S.A.'s assets above their book value (1.10x), reflecting positive investor sentiment about the company's future prospects.
Positive Asset Growth: Almirall S.A.'s assets grew by 0.9% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Almirall S.A. (2003–2024)
The table below shows the annual total assets of Almirall S.A. from 2003 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | €2.40 Billion ≈ $2.80 Billion |
+0.91% |
| 2023-12-31 | €2.37 Billion ≈ $2.78 Billion |
+10.58% |
| 2022-12-31 | €2.15 Billion ≈ $2.51 Billion |
+0.28% |
| 2021-12-31 | €2.14 Billion ≈ $2.50 Billion |
-6.52% |
| 2020-12-31 | €2.29 Billion ≈ $2.68 Billion |
-6.09% |
| 2019-12-31 | €2.44 Billion ≈ $2.85 Billion |
+2.10% |
| 2018-12-31 | €2.39 Billion ≈ $2.79 Billion |
+9.79% |
| 2017-12-31 | €2.18 Billion ≈ $2.54 Billion |
-22.78% |
| 2016-12-31 | €2.82 Billion ≈ $3.30 Billion |
+11.30% |
| 2015-12-31 | €2.53 Billion ≈ $2.96 Billion |
-0.32% |
| 2014-12-31 | €2.54 Billion ≈ $2.97 Billion |
+43.31% |
| 2013-12-31 | €1.77 Billion ≈ $2.07 Billion |
+30.72% |
| 2012-12-31 | €1.36 Billion ≈ $1.59 Billion |
-6.90% |
| 2011-12-31 | €1.46 Billion ≈ $1.70 Billion |
-5.21% |
| 2010-12-31 | €1.54 Billion ≈ $1.80 Billion |
+3.62% |
| 2009-12-31 | €1.48 Billion ≈ $1.73 Billion |
+6.20% |
| 2008-12-31 | €1.40 Billion ≈ $1.63 Billion |
-2.97% |
| 2007-12-31 | €1.44 Billion ≈ $1.68 Billion |
+29.16% |
| 2006-12-31 | €1.11 Billion ≈ $1.30 Billion |
-7.34% |
| 2005-12-31 | €1.20 Billion ≈ $1.41 Billion |
+41.62% |
| 2004-12-31 | €849.03 Million ≈ $992.61 Million |
+6.49% |
| 2003-12-31 | €797.27 Million ≈ $932.09 Million |
-- |
About Almirall S.A.
Almirall, S.A. operates as a skin health-focused biopharmaceutical company in Spain, Europe, the Middle East, the United States, Asia, and Africa. The company offers its products for skin diseases comprising Psoriasis, atopic dermatitis, acne, actinic keratosis, onychomycosis, androgenic alopecia, oncodermatology, and orphan indications, as well as for alimentary tract and metabolism; antiinfecti… Read more